The somatic mutation landscape of premalignant colorectal adenoma

Gut

Volumn 67, Issue 7, 2018, Pages 1299-1305

  Lin, Shu Hong ^a,b   Raju, Gottumukkala S ^a   Huff, Chad ^a   Ye, Yuanqing ^a   Gu, Jian ^a   Chen, Jiun Sheng ^a,b   Hildebrandt, Michelle A T ^a   Liang, Han ^b   Menter, David G ^a   Morris, Jeffery ^a   Hawk, Ernest ^a   Stroehlein, John R ^a   Futreal, Andrew ^a   Kopetz, Scott ^a   Mishra, Lopa ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; PRIORITY JOURNAL; RANDOM FOREST; SOMATIC MUTATION; TUMOR GROWTH; WHOLE EXOME SEQUENCING; ADENOCARCINOMA; ADENOMA; COLORECTAL TUMOR; GENETICS; MUTATION; PATHOLOGY; PRECANCER;

ADENOCARCINOMA; ADENOMA; ADULT; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PRECANCEROUS CONDITIONS; WHOLE EXOME SEQUENCING;

EID: 85047855158     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-313573     Document Type: Article

References (38)

1. Neugut AI, Jacobson JS, Rella VA. Prevalence and incidence of colorectal adenomas and cancer in asymptomatic persons. Gastrointest Endosc Clin N Am 1997;7:387-99.
2. Brenner H, Hoffmeister M, Stegmaier C, et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840, 149 screening colonoscopies. Gut 2007;56:1585-9.
3. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG , et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009;101:1412-22.
4. Zhu H, Zhang G, Yi X, et al. Histology subtypes and polyp size are associated with synchronous colorectal carcinoma of colorectal serrated polyps: a study of 499 serrated polyps. Am J Cancer Res 2015;5:363-74.
5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
6. Kato S, Lippman SM, Flaherty KT, et al. The conundrum of genetic "Drivers" in benign conditions. J Natl Cancer Inst 2016;108:djw036.
7. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546-58.
8. Van den Eynden J, Fierro AC , Verbeke LP, et al. SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering. BMC Bioinformatics 2015;16:125.
9. Wilks C, Cline MS, Weiler E, et al. The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data. Database 2014;2014:bau093.
10. Therneau T, Atkinson B. port) BR (author of initial R. Rpart: recursive partitioning and regression Trees. 2015. https:// cran. r- project. org/ web/ packages/ rpart/ index. html. (accessed 22 Apr 2016).
11. Cutler F original by LB and A, Wiener R port by AL and M. randomForest: Breiman and Cutler's Random Forests for Classification and Regression. 2015. https:// cran. r- project. org/ web/ packages/ randomForest/ index. html. (accessed 22 Apr 2016).
12. Archer E. rfPermute: estimate Permutation p-Values for Random Forest Importance Metrics. 2016. https:// cran. r- project. org/ web/ packages/ rfPermute/ index. html. (accessed 22 Apr 2016).
13. Bläker H, Hofmann WJ, Rieker RJ, et al. Beta-catenin accumulation and mutation of the CTNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999;25:399-402.
14. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
15. Matsuda K, Shimada A, Yoshida N, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 2007;109:5477-80.
16. Bourdeaut F, Hérault A, Gentien D, et al. Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. J Med Genet 2010;47:859-62.
17. Shitoh K, Konishi F, Iijima T, et al. A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol 1999;52:695-6.
18. Legoix P, Bluteau O, Bayer J, et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999;18:4044-6.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995;57:289-300.
20. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014;25:304-17.
21. Kaminsky EB, Kaul V, Paschall J, et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet Med 2011;13:777-84.
22. Hashimoto T, Kato M, Shimomura T, et al. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. Febs J 2010;277:4888-900.
23. Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011;17:472-82.
24. Berens EB, Sharif GM, Schmidt MO, et al. Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion. Oncogene 2017;36:593-605.
25. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectaltumor development. N Engl J Med 1988;319:525-32.
26. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-8.
27. Ahadova A, von Knebel Doeberitz M, Bläker H, et al. CTNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome. Fam Cancer 2016;15:579-86.
28. Samowitz WS, Powers MD, Spirio LN, et al. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999;59:1442-4.
29. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008;27:2801-9.
30. Huels DJ, Ridgway RA, Radulescu S, et al. E-cadherin can limit the transforming properties of activating β-catenin mutations. Embo J 2015;34:2321-33.
31. Nikolaev SI, Sotiriou SK, Pateras IS, et al. A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res 2012;72:6279-89.
32. Zhou D, Yang L, Zheng L, et al. Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. PLoS One 2013;8:e53310.
33. Vaqué JP, Martínez N, Varela I, et al. Colorectal adenomas contain multiple somatic mutations that do not coincide with synchronous adenocarcinoma specimens. PLoS One 2015;10:e0119946.
34. Chen J, Raju GS, Jogunoori W, et al. Mutational profiles reveal an aberrant TGF-β-CEA regulated pathway in colon adenomas. PLoS One 2016;11:e0153933.
35. Borras E, San Lucas FA, Chang K, et al. Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res 2016;9:417-27.
36. Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology 1996;110:748-55.
37. Szylberg Ł, Janiczek M, Popiel A, et al. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. Gastroenterol Res Pract 2015;2015:573814.
38. Sweetser S, Jones A, Smyrk TC, et al. Sessile serrated polyps are precursors of Colon carcinomas with deficient DNA mismatch repair. Clin Gastroenterol Hepatol 2016;14:1056-9.